Anti-DLL3 antibody drug conjugates
AssigneeStemcentrx, Inc.
InventorsRobert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
Life of this patent
Estimating the term…
Abstract
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Claims25
-20. (canceled)
An antibody drug conjugate of the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof, wherein:
- M comprises an anti-DLL3 antibody that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO:
- 3 or 4;
- L comprises an optional linker;
- D comprises a radioisotope;
- and
- n is an integer from 1 to 20.
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-DLL3 antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:
- M comprises an anti-DLL3 antibody;
- L comprises an optional linker;
- D comprises a radioisotope;
- and
- n is an integer from 1 to 20.
A method of diagnosing a DLL3+ tumor in a subject comprising the steps of:
- (a) contacting a tumor sample obtained from the subject with an antibody drug conjugate of the formula M-[L-D]n, wherein
- M comprises an anti-DLL3 antibody;
- L comprises an optional linker;
- D comprises a radioisotope;
- and
- n is an integer from 1 to 20;
- and
- (b) detecting the radioisotope.
Dependencies are inferred from the claim text.